** At least six brokerages start coverage on medical supplies maker and distributor Medline MDLN.O with bullish ratings as industry-mandated quiet period ends
** Medline made its public-market debut in December, valuing co at $46 billion in the largest U.S. IPO since Rivian's RIVN.O 2021 listing
** JPM says MDLN’s recent market share gains are likely to endure, with co well-placed to keep winning business by offering cost savings alongside strong service
** Jefferies says co is expected to grow at high single‑digit pace or better, with growth split evenly between existing customers and new client wins
** Trading price of $40.52 as of Friday's close is higher than IPO price of $29
** Ratings and PTs on the stock:
Brokerage | Rating | PT |
J.P. Morgan | Overweight | $50 |
Leerink Partners | Outperform | $48 |
Baird | Outperform | $48 |
RBC | Outperform | $47 |
Piper Sandler | Overweight | $50 |
Jefferies | Buy | $50 |
(Reporting by Kanishka Ajmera in Bengaluru)
((mail to: Kanishka.Ajmera@thomsonreuters.com))